KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) Operating Expenses (2016 - 2025)

Historic Operating Expenses for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q4 2025 value amounting to $155.6 million.

  • CRISPR Therapeutics AG's Operating Expenses rose 5519.5% to $155.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $668.1 million, marking a year-over-year increase of 3258.76%. This contributed to the annual value of $668.1 million for FY2025, which is 3258.73% up from last year.
  • According to the latest figures from Q4 2025, CRISPR Therapeutics AG's Operating Expenses is $155.6 million, which was up 5519.5% from $132.9 million recorded in Q3 2025.
  • In the past 5 years, CRISPR Therapeutics AG's Operating Expenses ranged from a high of $230.2 million in Q2 2025 and a low of $100.3 million during Q4 2024
  • In the last 5 years, CRISPR Therapeutics AG's Operating Expenses had a median value of $145.2 million in 2024 and averaged $149.1 million.
  • Per our database at Business Quant, CRISPR Therapeutics AG's Operating Expenses surged by 7103.66% in 2021 and then crashed by 2743.89% in 2023.
  • CRISPR Therapeutics AG's Operating Expenses (Quarter) stood at $158.6 million in 2021, then dropped by 17.06% to $131.5 million in 2022, then grew by 0.06% to $131.6 million in 2023, then dropped by 23.81% to $100.3 million in 2024, then skyrocketed by 55.2% to $155.6 million in 2025.
  • Its last three reported values are $155.6 million in Q4 2025, $132.9 million for Q3 2025, and $230.2 million during Q2 2025.